Over the past several years, nanomedicines have become an important area of focus for drug delivery and therapeutics in the treatment of various forms of cancer. Nanomedicines have shown promise in several areas, which include the ability to effectively cross biological barriers, actively target cancer cells, and increase drug accumulation. Through more specific targeting of cancer cells, sparing healthy cells and tissues, nanomedicine can also reduce some of the side effects experienced with more traditional chemotherapy and radiation. 
While several cancer nanomedicines have made it to market, they have largely received approval based on enhanced safety, rather than efficacy and improvement on survival rates. Many nanomedicines show significant anti-cancer activity in pre-clinical studies, but these promising results often do not carry over to clinical trials. 
Further study and development of nanomedicines is critical in the effort to find more effective forms of cancer treatment. 
Technology Overview 
This technology involves the use of human dermal fibroblasts (HDF) for the synthesis of noble metal nanoparticles, including gold, palladium, platinum and bimetallic formulations, using an eco-friendly approach. The research team is investigating the synthesis of these nanoparticles both intracellularly and extracellularly in different human living cell lines, (both healthy cells and cancer cells). They are also examining the effects of the precursor metal ions on cell viability and cell morphology. They intend to pursue the development of HDF synthesized nanoparticles for personalized cancer treatment. 
- Nanoparticles derived from a patient’s own cells is a novel approach 
- Production uses green chemistry with no toxic chemicals/reagents 
- Potential to withstand extreme environmental conditions 
- Cancer therapy 
- Licensing
- Partnering
- Research collaboration
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
David Medina Cruz
Junjiang Chen
Thomas Webster